Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Genus plc (GNS.L)
GBp2,182.00
+12.00 (+0.55%)
GB LSE Healthcare Biotechnology
Address
Matrix House RG21 4DZ
Basingstoke, GB
Basingstoke, GB
CEO
Jorgen Kokke
Website
genusplc.com
IPO
2000-07-06
ISIN GB0002074580
Also trades on
London Stock Exchange · GNS.L (GBp)
Other OTC · GENSF (USD)
Description
Genus plc is a global animal genetics company with operations spanning North America, Latin America, the UK, continental Europe, the Middle East, Russia, Africa, and Asia. The business is divided into three key segments: Genus PIC, Genus ABS, and Genus Research and Development. Under its PIC brand, the company provides breeding stock, including sows, boars, and semen, to develop pigs with specific characteristics optimized for pork production. Similarly, for cattle, its ABS, Genus, and Bovec brands offer bull semen and embryos designed to produce calves with advantageous traits for either milk or beef output. Farmers also benefit from a range of specialized technical services, such as semen sexing and reproductive solutions. Genus plc is also strategically collaborating with Beijing Capital Agribusiness Co. Ltd on the research, development, and regulatory approval of porcine reproductive and respiratory syndrome virus (PRRSV)-resistant pigs in China. The company was established in 1994 and is based in Basingstoke, United Kingdom.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
GBp2,182.00
+12.00 (+0.55%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
231.4K
Beta
0.90
Float Shares
65.07M
Free Float %
98.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.27% | -6.67% | -0.68% | -20.14% | -11.48% | -10.29% | +15.53% | -6.73% | -54.44% | +53.66% | +2,306.20% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2,182.00
DCF (Unlevered)
1,391.56
-36.2%
DCF (Levered)
346.52
-84.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | +1 |
| Buy | 8 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.65
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+0.6% Q4'25: +0.6% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+141.7% ★ Q4'25: +120.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+8.4% ★ Q4'25: +5.2% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+7.3% ★ Q4'25: +10.7% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+4.8% ★ Q4'25: +14.7% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+1.0% ★ Q4'25: +1.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.84× Q4'25: 1.21× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2007 actual |
Jun 2008 actual |
Jun 2009 actual |
Jun 2010 actual |
Jun 2011 actual |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 12 Rev. Ana. 9 EPS Ana. |
Jun 2027 12 Rev. Ana. 9 EPS Ana. |
Jun 2028 9 Rev. Ana. 4 EPS Ana. |
Jun 2029 4 Rev. Ana. 1 EPS Ana. |
Jun 2030 5 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
233.80M
est: 267.66M (-12.6%)
|
247.10M
est: 248.56M (-0.6%)
|
280.40M
est: 283.25M (-1.0%)
|
285.30M
est: 281.48M (+1.4%)
|
309.90M
est: 312.14M (-0.7%)
|
341.80M
est: 338.43M (+1.0%)
|
345.30M
est: 360.78M (-4.3%)
|
372.20M
est: 376.93M (-1.3%)
|
398.50M
est: 394.04M (+1.1%)
|
388.30M
est: 397.54M (-2.3%)
|
459.10M
est: 448.95M (+2.3%)
|
470.30M
est: 476.04M (-1.2%)
|
488.50M
est: 484.99M (+0.7%)
|
551.40M
est: 522.13M (+5.6%)
|
574.30M
est: 570.66M (+0.6%)
|
593.40M
est: 563.95M (+5.2%)
|
689.70M
est: 692.65M (-0.4%)
|
668.80M
est: 671.28M (-0.4%)
|
672.80M
est: 674.87M (-0.3%)
|
677.40M
644.27M – 725.54M
+0.4% YoY
|
690.01M
625.12M – 748.03M
+1.9% YoY
|
705.01M
704.99M – 705.04M
+2.2% YoY
|
750.73M
696.92M – 809.02M
+6.5% YoY
|
771.00M
715.73M – 830.86M
+2.7% YoY
|
| EBITDA |
41.50M
est: 35.02M (+18.5%)
|
39.30M
est: 21.27M (+84.8%)
|
43.00M
est: 33.96M (+26.6%)
|
57.30M
est: 29.61M (+93.5%)
|
54.10M
est: 50.33M (+7.5%)
|
68.00M
est: 53.02M (+28.3%)
|
44.40M
est: 70.36M (-36.9%)
|
-47.70M
est: 52.87M (-190.2%)
|
-38.50M
est: 49.45M (-177.9%)
|
51.40M
est: 71.72M (-28.3%)
|
57.70M
est: 89.60M (-35.6%)
|
31.40M
est: 67.08M (-53.2%)
|
65.50M
est: 67.75M (-3.3%)
|
68.00M
est: 41.82M (+62.6%)
|
82.30M
est: 102.78M (-19.9%)
|
79.80M
est: 110.30M (-27.6%)
|
87.50M
est: 121.90M (-28.2%)
|
73.70M
est: 133.25M (-44.7%)
|
93.70M
est: 88.00M (+6.5%)
|
88.62M
84.29M – 94.92M
+0.7% YoY
|
90.27M
81.78M – 97.86M
+1.9% YoY
|
92.23M
92.23M – 92.24M
+2.2% YoY
|
98.21M
91.17M – 105.84M
+6.5% YoY
|
100.86M
93.63M – 108.70M
+2.7% YoY
|
| EBIT |
31.70M
est: 17.51M (+81.0%)
|
30.60M
est: 26.37M (+16.0%)
|
33.00M
est: 29.86M (+10.5%)
|
46.10M
est: 32.00M (+44.1%)
|
44.20M
est: 51.65M (-14.4%)
|
57.10M
est: 48.57M (+17.6%)
|
38.70M
est: 57.78M (-33.0%)
|
-58.60M
est: 38.87M (-250.8%)
|
-50.90M
est: 44.36M (-214.7%)
|
37.20M
est: 60.02M (-38.0%)
|
44.80M
est: 65.96M (-32.1%)
|
12.20M
est: 40.61M (-70.0%)
|
44.30M
est: 8.34M (+431.1%)
|
45.40M
est: 9.35M (+385.4%)
|
60.30M
est: 52.27M (+15.4%)
|
56.60M
est: 56.09M (+0.9%)
|
43.80M
est: 61.99M (-29.3%)
|
26.80M
est: 67.76M (-60.5%)
|
49.00M
est: 44.02M (+11.3%)
|
44.33M
42.16M – 47.48M
+0.7% YoY
|
45.15M
40.91M – 48.95M
+1.9% YoY
|
46.13M
46.13M – 46.14M
+2.2% YoY
|
49.13M
45.60M – 52.94M
+6.5% YoY
|
50.45M
46.84M – 54.37M
+2.7% YoY
|
| Net Income |
14.60M
est: 18.34M (-20.4%)
|
17.70M
est: 13.56M (+30.5%)
|
17.90M
est: 20.17M (-11.3%)
|
27.50M
est: 17.79M (+54.6%)
|
29.20M
est: 30.22M (-3.4%)
|
39.50M
est: 31.66M (+24.8%)
|
27.00M
est: 42.11M (-35.9%)
|
28.90M
est: 28.21M (+2.5%)
|
39.90M
est: 30.67M (+30.1%)
|
49.30M
est: 40.25M (+22.5%)
|
32.80M
est: 55.49M (-40.9%)
|
42.70M
est: 34.87M (+22.5%)
|
7.80M
est: 43.44M (-82.0%)
|
35.30M
est: 8.39M (+320.9%)
|
47.30M
est: 44.47M (+6.4%)
|
40.90M
est: 47.72M (-14.3%)
|
33.30M
est: 33.30M (+0.0%)
|
7.90M
est: 7.90M (+0.0%)
|
19.30M
est: 19.30M (+0.0%)
|
71.83M
66.48M – 77.19M
+272.2% YoY
|
72.65M
65.14M – 80.16M
+1.1% YoY
|
77.85M
66.73M – 88.97M
+7.2% YoY
|
89.11M
80.81M – 98.11M
+14.5% YoY
|
87.37M
79.22M – 96.18M
-2.0% YoY
|
| SGA |
58.80M
est: 33.04M (+78.0%)
|
64.50M
est: 1.30M (+4,861.1%)
|
72.20M
est: 2.73M (+2,539.9%)
|
80.10M
est: 102.46M (-21.8%)
|
86.60M
est: 92.97M (-6.8%)
|
47.30M
est: 128.91M (-63.3%)
|
59.70M
est: 157.46M (-62.1%)
|
57.50M
est: 55.37M (+3.8%)
|
64.30M
est: 57.94M (+11.0%)
|
71.10M
est: 62.54M (+13.7%)
|
77.90M
est: 77.55M (+0.4%)
|
81.60M
est: 81.54M (+0.1%)
|
71.90M
est: 81.99M (-12.3%)
|
88.00M
est: 76.33M (+15.3%)
|
96.70M
est: 6.37M (+1,418.3%)
|
89.40M
est: 6.83M (+1,208.1%)
|
93.10M
est: 7.55M (+1,132.5%)
|
109.10M
est: 8.26M (+1,221.3%)
|
—
est: 83.03M (-100.0%)
|
83.61M
79.52M – 89.55M
+0.7% YoY
|
85.17M
77.16M – 92.33M
+1.9% YoY
|
87.02M
87.02M – 87.02M
+2.2% YoY
|
92.66M
86.02M – 99.86M
+6.5% YoY
|
95.16M
88.34M – 102.55M
+2.7% YoY
|
| EPS |
0.27
est: 0.27 (-1.6%)
|
0.31
est: 0.33 (-6.8%)
|
0.30
est: 0.36 (-16.4%)
|
0.46
est: 0.36 (+29.0%)
|
0.49
est: 0.42 (+16.0%)
|
0.66
est: 0.52 (+26.1%)
|
0.39
est: 0.56 (-30.4%)
|
0.48
est: 0.46 (+3.4%)
|
0.66
est: 0.54 (+22.0%)
|
0.81
est: 0.57 (+41.9%)
|
0.54
est: 0.65 (-17.2%)
|
0.70
est: 0.74 (-5.0%)
|
0.12
est: 0.73 (-83.5%)
|
0.54
est: 0.80 (-32.4%)
|
0.73
est: 0.99 (-26.6%)
|
0.63
est: 0.82 (-22.7%)
|
0.51
est: 0.80 (-36.1%)
|
0.12
est: 0.66 (-81.7%)
|
0.29
est: 0.78 (-63.0%)
|
1.05
0.99 – 1.15
+34.0% YoY
|
1.04
0.97 – 1.20
-1.3% YoY
|
1.13
1.00 – 1.33
+9.3% YoY
|
1.33
1.21 – 1.47
+17.7% YoY
|
1.31
1.19 – 1.44
-2.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-01 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
97.22M
OE per share TTM
1.46
Owner's Yield
6.32%
Maintenance CapEx ratio
16.19%
Maint CapEx / Avg PPE
23.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 93 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P UK Dividend Aristocrats UCITS ETF (Dist) UKDV.L | 0.93% | 1.33M | 0.30% |
| 2 | Amundi Prime UK Mid & Small Cap UCITS ETF DR - GBP (D) PRUK.L | 0.72% | 3.07M | 0.05% |
| 3 | Vanguard FTSE 250 UCITS ETF (GBP) Distributing VMID.DE | 0.51% | 13.52M | 0.10% |
| 4 | Vanguard FTSE 250 UCITS ETF VMIG.MI | 0.51% | 13.52M | 0.10% |
| 5 | Xtrackers FTSE 250 UCITS ETF 1D XMCX.L | 0.47% | 181.1K | 0.15% |
| 6 | VanEck Agribusiness ETF MOO | 0.47% | 4.52M | 0.56% |
| 7 | Invesco FTSE 250 UCITS ETF S250.L | 0.44% | 157.4K | 0.12% |
| 8 | iShares FTSE 250 UCITS ETF MIDD.L | 0.44% | 3.73M | 0.40% |
| 9 | HSBC FTSE 250 UCITS ETF HMCX.L | 0.43% | 291.5K | 0.09% |
| 10 | iShares Agribusiness UCITS ETF ISAG.L | 0.40% | 1.85M | 0.55% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
14.0K
Shares Outstanding
66.41M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jorgen Kokke | Chief Executive Officer & Executive Director | 2M | male |
| Andrew Paul Russell | Chief Financial Officer & Executive Director | 949.0K | male |
| Elena Rice | Head of R&D and Chief Scientific Officer | — | — |
| Janet Duane | Group Financial Controller | — | female |
| Jim Low | Chief Operating Officer of Genus ABS | — | male |
| Lucie Mary Katja Grant | Group General Counsel & Company Secretary | — | female |
| Mark Birri | Chief Corporate Development Officer | — | male |
| Matt Culbertson | Chief Operating Officer | — | — |
| Angelle R. Rosata | Chief Human Resources Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GNS.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
